Analysts’ Viewpoint
Valganciclovir is an antiviral medication used to treat cytomegalovirus (CMV). Increase in the number of people with cytomegalovirus (CMV) retinitis and organ transplant is driving the demand for valganciclovir. Favorable government support in terms of reimbursement and research funding is another factor propelling the global valganciclovir market. Development of oral valganciclovir (VGCV) in infants aged ≤2 months with congenital cytomegalovirus (CMV) disease presents significant opportunities in the market.
Companies are collaborating with academic research institutes to carry out research in order to expand applications of VGCV drug in different indication such as glioblastoma. Key players in the industry are striving to introduce generic drug of VGCV, especially in tablet form, to cater to the growing demand for the drug to treat infection after organ transplant.
Valganciclovir is a prodrug for ganciclovir. Antiviral VGCV is available in tablet and solution forms. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterase. The medication is available in the market in its active form, as valganciclovir hcl, which is used to treat symptoms of cytomegalovirus (CMV) retinitis, infection in the eyes of people with acquired immunodeficiency syndrome (AIDS), and to prevent CMV disease in patients who have undergone organ transplant (e.g., heart, kidney, or kidney-pancreas transplant).
Solid organ transplantation saves the lives of patients affected by terminal organ failures and improves the quality of life. Organ transplantations have gradually improved in the last two decades and usually provide excellent results in children and young adults. Transplantations are increasingly challenging among elderly transplant patients with comorbidities. Renal transplantation increases patient survival over that with dialysis. Moreover, transplants that save lives are indispensable to treat patients with liver, heart, or lung irreversible diseases.
In transplant patients, the cytomegalovirus virus (CMV) can cause major health issues. According to a study published in NCBI (2017), the occurrence of CMV infection varies between 10% and 70% at various renal transplant centers across the globe.
According to the Global Observatory on Donation and Transplantation (GODT), more than 146,000 solid organ transplants are carried out across the world each year, including 95,479 kidney transplants. The need for kidney transplants is expected to increase in all WHO regions in the next few years. This is expected to propel the global valganciclovir market during the forecast period.
Cytomegalovirus (CMV) retinitis is the most common ocular infection in patients with acquired immunodeficiency syndrome even in the era of highly active antiretroviral therapy (HAART). CMV retinitis (CMVR) was a common cause of blindness among patients with HIV/AIDS. Even when CMVR is suspected, treatment is rarely available in low- and middle-income countries (LMIC). Oral therapy, valganciclovir, replaced intravenous therapy as the standard of care for CMVR.
It is primarily used for systemic therapy as compared to other drugs for treatment of cytomegalovirus infections owing to the ease of administration and absence of catheter-related complications. This has increased the demand for VGCV drugs across the world for the treatment of AIDS-related cytomegalovirus retinitis.
Based on distribution channel, the global valganciclovir market segmentation comprises hospital pharmacies and retail pharmacies. The hospital pharmacies segment accounted for more than 80% share in 2021. The segment is anticipated to grow at a rapid pace in the near future in Asia Pacific and the Middle East due to availability of a range of products and treatments under one roof.
North America held significant market share in 2021. Rise in awareness and adoption of quick treatment are propelling market progress. Increase in organ transplant is another factor that drives market development in the region, especially in the U.S. According to the U.S. Department of Health & Human Services, 41,354 organ transplants were performed in the country in 2021, an increase of 5.9% over 2020. This was the first time the annual total exceeded 40,000.
Awareness about the benefits of VGCV in countries such as India and Indonesia and surge in government investment in healthcare systems in countries in South Asia are anticipated to augment market expansion in Asia Pacific in the next few years. New cases of HIV in Indonesia have risen from 7,000 per year in 2006 to 48,000 per year in 2017.
The global valganciclovir market is fragmented, with the presence of large number of small and big players. Key players operating in the industry are F. Hoffmann-La Roche AG, Endo International plc, Dr. Reddy's Laboratories, Cipla Limited, Alniche Life Sciences Pvt. Ltd., Anthem Biosciences Private Limited, Merck & Co., Inc., Panacea Biotec Ltd., and Camber Pharmaceuticals, Inc. Leading players have adopted strategies such as new product development, product approvals, product launches, partnerships, and mergers.
Key players have been profiled in the valganciclovir market report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 288.6 Mn |
|
Forecast (Value) in 2031 |
More than US$ 484.1 Mn |
|
Growth Rate (CAGR) |
4.6% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, etc. |
|
Competition Landscape |
Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials |
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The industry was valued at US$ 288.6 Mn in 2021
It is projected to reach more than US$ 484.1 Mn by 2031
The CAGR is anticipated be 4.6% from 2022 to 2031
Increase in organ transplants, rise in prevalence of retinitis in HIV/AIDS patients, and surge in launch of generic drugs.
The cytomegalovirus retinitis segment held more than 53.0% share in 2021
North America is expected to account for dominant share from 2022 to 2031.
F. Hoffmann-La Roche AG, Endo International plc, Dr. Reddy's Laboratories, Cipla Limited, Alniche Life Sciences Pvt. Ltd, Anthem Biosciences Private Limited, Merck & Co., Inc., Panacea Biotec Ltd. and Camber Pharmaceuticals, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Valganciclovir Market
4. Market Overview
4.1. Introduction
4.1.1. Patient Age Group
4.1.2. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Valganciclovir Market Analysis and Forecast, 2017–2031
4.3.1. Global Valganciclovir Market Revenue Projection (US$ Mn)
5. Market Outlook
5.1. Valganciclovir Virus Disease Prevalence
5.2. Key Industry Development
5.3. COVID-19 Impact Analysis
6. Global Valganciclovir Market Analysis and Forecast, by Patient Age Group
6.1. Key Findings/Developments
6.2. Introduction & Definition
6.3. Global Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
6.3.1. Adult Patients
6.3.2. Pediatric Patients
6.4. Global Valganciclovir Market Attractiveness Analysis, by Patient Age Group
7. Global Valganciclovir Market Analysis and Forecast, by Application
7.1. Key Findings/Developments
7.2. Introduction & Definition
7.3. Global Valganciclovir Market Value Forecast, by Application, 2017–2031
7.3.1. Organ Transplant
7.3.2. Cytomegalovirus Retinitis
7.4. Global Valganciclovir Market Attractiveness Analysis, by Application
8. Global Valganciclovir Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings/Developments
8.2. Introduction & Definition
8.3. Global Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.4. Global Valganciclovir Market Attractiveness Analysis, by Distribution Channel
9. Global Valganciclovir Market Analysis and Forecast, by Region
9.1. Geographical Representation
9.2. Global Valganciclovir Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Valganciclovir Market Attractiveness Analysis, by Region
10. North America Valganciclovir Market Analysis and Forecast
10.1. North America Valganciclovir Market Value Share Analysis, by Country, 2017–2031
10.2. North America Valganciclovir Market Value Forecast, by Country, 2017–2031
10.2.1. U.S.
10.2.2. Canada
10.3. North America Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031
10.4. North America Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
10.4.1. Adult Patients
10.4.2. Pediatric Patients
10.5. North America Valganciclovir Market Value Share Analysis, by Application, 2021–2031
10.6. North America Valganciclovir Market Value Forecast, by Application, 2017–2031
10.6.1. Organ Transplant
10.6.2. Cytomegalovirus Retinitis
10.7. North America Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031
10.8. North America Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
10.8.1. Hospital Pharmacies
10.8.2. Retail Pharmacies
10.9. North America Valganciclovir Market Attractiveness Analysis (2022–2031)
10.9.1. By Country
10.9.2. By Patient Age Group
10.9.3. By Application
10.9.4. By Distribution Channel
11. Europe Valganciclovir Market Analysis and Forecast
11.1. Europe Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031
11.1.1. Germany
11.1.2. France
11.1.3. U.K.
11.1.4. Spain
11.1.5. Italy
11.1.6. Rest of Europe
11.2. Europe Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031
11.3. Europe Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
11.3.1. Adult Patients
11.3.2. Pediatric Patients
11.4. Europe Valganciclovir Market Value Share Analysis, by Application, 2021–2031
11.5. Europe Valganciclovir Market Value Forecast, by Application, 2017–2031
11.5.1. Organ Transplant
11.5.2. Cytomegalovirus Retinitis
11.6. Europe Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031
11.7. Europe Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.8. Europe Valganciclovir Market Attractiveness Analysis (2022–2031)
11.8.1. By Country/Sub-region
11.8.2. By Patient Age Group
11.8.3. By Application
11.8.4. By Distribution Channel
12. Asia Pacific Valganciclovir Market Analysis and Forecast
12.1. Asia Pacific Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031
12.1.1. China
12.1.2. Japan
12.1.3. India
12.1.4. Australia & New Zealand
12.1.5. Rest of Asia Pacific
12.2. Asia Pacific Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031
12.3. Asia Pacific Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
12.3.1. Adult Patients
12.3.2. Pediatric Patients
12.4. Asia Pacific Valganciclovir Market Value Share Analysis, by Application, 2021–2031
12.5. Asia Pacific Valganciclovir Market Value Forecast, by Application, 2017–2031
12.5.1. Organ Transplant
12.5.2. Cytomegalovirus Retinitis
12.6. Asia Pacific Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031
12.7. Asia Pacific Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.8. Asia Pacific Valganciclovir Market Attractiveness Analysis (2022–2031)
12.8.1. By Country/Sub-region
12.8.2. By Patient Age Group
12.8.3. By Application
12.8.4. By Distribution Channel
13. Latin America Valganciclovir Market Analysis and Forecast
13.1. Latin America Valganciclovir Market Value Forecast, by Country/Sub-region, 2017-2027
13.1.1. Brazil
13.1.2. Mexico
13.1.3. Rest of Latin America
13.2. Latin America Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031
13.3. Latin America Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
13.3.1. Adult Patients
13.3.2. Pediatric Patients
13.4. Latin America Valganciclovir Market Value Share Analysis, by Application, 2021–2031
13.5. Latin America Valganciclovir Market Value Forecast, by Application, 2017–2031
13.5.1. Organ Transplant
13.5.2. Cytomegalovirus Retinitis
13.6. Latin America Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031
13.7. Latin America Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
13.7.1. Hospital Pharmacies
13.8. Latin America Valganciclovir Market Attractiveness Analysis (2022–2031)
13.8.1. By Country/Sub-region
13.8.2. By Patient Age Group
13.8.3. By Application
13.8.4. By Distribution Channel
14. Middle East & Africa Valganciclovir Market Analysis and Forecast
14.1. Middle East & Africa Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031
14.1.1. GCC Countries
14.1.2. South Africa
14.1.3. Rest of Middle East & Africa
14.2. Middle East & Africa Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031
14.3. Middle East & Africa Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
14.3.1. Adult Patients
14.3.2. Pediatric Patients
14.4. Middle East & Africa Valganciclovir Market Value Share Analysis, by Application, 2021–2031
14.5. Middle East & Africa Valganciclovir Market Value Forecast, by Application, 2017–2031
14.5.1. Organ Transplant
14.5.2. Cytomegalovirus Retinitis
14.6. Middle East & Africa Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031
14.7. Middle East & Africa Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
14.7.1. Hospital Pharmacies
14.7.2. Retail Pharmacies
14.8. Middle East & Africa Valganciclovir Market Attractiveness Analysis (2022–2031)
14.8.1. By Country/Sub-region
14.8.2. By Patient Age Group
14.8.3. By Application
14.8.4. By Distribution Channel
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.2.1. Endo International plc (HQ, Business Segments, Employee Strength)
15.2.1.1. Company Details
15.2.1.2. Company Description
15.2.1.3. Business Overview
15.2.1.4. SWOT Analysis
15.2.1.5. Financial Analysis
15.2.1.6. Strategic Overview
15.2.2. Dr. Reddy's Laboratories AG (HQ, Business Segments, Employee Strength)
15.2.2.1. Company Details
15.2.2.2. Company Description
15.2.2.3. Business Overview
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. F. Hoffmann-La Roche AG (HQ, Business Segments, Employee Strength)
15.2.3.1. Company Details
15.2.3.2. Company Description
15.2.3.3. Business Overview
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Cipla Limited (HQ, Business Segments, Employee Strength)
15.2.4.1. Company Details
15.2.4.2. Company Description
15.2.4.3. Business Overview
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Alniche Life Sciences Pvt. Ltd. (HQ, Business Segments, Employee Strength)
15.2.5.1. Company Details
15.2.5.2. Company Description
15.2.5.3. Business Overview
15.2.5.4. SWOT Analysis
15.2.5.5. Financial Analysis
15.2.5.6. Strategic Overview
15.2.6. Anthem Biosciences Private Limited (HQ, Business Segments, Employee Strength)
15.2.6.1. Company Details
15.2.6.2. Company Description
15.2.6.3. Business Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Financial Analysis
15.2.6.6. Strategic Overview
15.2.7. Merck & Co., Inc. (HQ, Business Segments, Employee Strength)
15.2.7.1. Company Details
15.2.7.2. Company Description
15.2.7.3. Business Overview
15.2.7.4. SWOT Analysis
15.2.7.5. Financial Analysis
15.2.7.6. Strategic Overview
15.2.8. Panacea Biotec Ltd. (HQ, Business Segments, Employee Strength)
15.2.8.1. Company Details
15.2.8.2. Company Description
15.2.8.3. Business Overview
15.2.8.4. SWOT Analysis
15.2.8.5. Financial Analysis
15.2.8.6. Strategic Overview
15.2.9. Camber Pharmaceuticals, Inc. (HQ, Business Segments, Employee Strength)
15.2.9.1. Company Details
15.2.9.2. Company Description
15.2.9.3. Business Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Financial Analysis
15.2.9.6. Strategic Overview
15.2.10. Healthiza Lifescience Private Limited (HQ, Business Segments, Employee Strength)
15.2.10.1. Company Details
15.2.10.2. Company Description
15.2.10.3. Business Overview
15.2.10.4. SWOT Analysis
15.2.10.5. Financial Analysis
15.2.10.6. Strategic Overview
List of Tables
Table 01: Global Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031
Table 02: Global Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Valganciclovir Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031
Table 07: North America Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 08: North America Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Valganciclovir Market Revenue (US$ Mn) Forecast, by Country,/Sub-region, 2017–2031
Table 10: Europe Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031
Table 11: Europe Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 12: Europe Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031
Table 14: Asia Pacific Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031
Table 15: Asia Pacific Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 16: Asia Pacific Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031
Table 18: Latin America Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031
Table 19: Latin America Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 20: Latin America Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031
Table 22: Middle East & Africa Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031
Table 23: Middle East & Africa Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Middle East & Africa Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Valganciclovir Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Valganciclovir Market Value Share, by Region, 2021
Figure 03: Global Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021 and 2031
Figure 04: Global Valganciclovir Market Attractiveness Analysis, by Patient Age Group 2022–2031
Figure 05: Global Valganciclovir Market Revenue (US$ Mn), by Adult Patients, 2017–2031
Figure 06: Global Valganciclovir Market Revenue (US$ Mn), by Pediatric Patients, 2017–2031
Figure 07: Global Valganciclovir Market Value Share Analysis, by Application, 2021 and 2031
Figure 08: Global Valganciclovir Market Attractiveness Analysis, by Application, 2022–2031
Figure 09: Global Valganciclovir Market Revenue (US$ Mn), by Organ Transplant, 2017–2031
Figure 10: Global Valganciclovir Market Revenue (US$ Mn), by Cytomegalovirus Retinitis, 2017–2031
Figure 11: Global Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 12: Global Valganciclovir Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 13: Global Valganciclovir Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 14: Global Valganciclovir Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 15: Global Valganciclovir Market Value Share Analysis, by Region, 2021 and 2031
Figure 16: Global Valganciclovir Market Attractiveness Analysis, by Region, 2022–2031
Figure 17: North America Valganciclovir Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 18: North America Valganciclovir Market Value Share (%), by Country, 2021 and 2031
Figure 19: North America Valganciclovir Market Attractiveness Analysis, by Country, 2022–2031
Figure 20: North America Valganciclovir Market Value Share (%), by Patient Age Group, 2021 and 2031
Figure 21: North America Valganciclovir Market Attractiveness Analysis, by Patient Age Group, 2022–2031
Figure 22: North America Valganciclovir Market Value Share Analysis, by Application, 2021 and 2031
Figure 23: North America Valganciclovir Market Attractiveness Analysis, by Application, 2022–2031
Figure 24: North America Valganciclovir Market Value Share (%), by Distribution Channel, 2021 and 2031
Figure 25: North America Valganciclovir Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 26: Europe Valganciclovir Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 27: Europe Valganciclovir Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 28: Europe Valganciclovir Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 29: Europe Valganciclovir Market Value Share (%), by Patient Age Group, 2021 and 2031
Figure 30: Europe Valganciclovir Market Attractiveness Analysis, by Patient Age Group, 2022–2031
Figure 31: Europe Valganciclovir Market Value Share Analysis, by Application, 2021 and 2031
Figure 32: Europe Valganciclovir Market Attractiveness Analysis, by Application, 2022–2031
Figure 33: Europe Valganciclovir Market Value Share (%), by Distribution Channel, 2021 and 2031
Figure 34: Europe Valganciclovir Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 35: Asia Pacific Valganciclovir Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 36: Asia Pacific Valganciclovir Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 37: Asia Pacific Valganciclovir Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 38: Asia Pacific Valganciclovir Market Value Share (%), by Patient Age Group, 2021 and 2031
Figure 39: Asia Pacific Valganciclovir Market Attractiveness Analysis, by Patient Age Group, 2022–2031
Figure 40: Asia Pacific Valganciclovir Market Value Share Analysis, by Application, 2021 and 2031
Figure 41: Asia Pacific Valganciclovir Market Attractiveness Analysis, by Application, 2022–2031
Figure 42: Asia Pacific Valganciclovir Market Value Share (%), by Distribution Channel, 2021 and 2031
Figure 43: Asia Pacific Valganciclovir Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 44: Latin America Valganciclovir Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 45: Latin America Valganciclovir Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 46: Latin America Valganciclovir Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 47: Latin America Valganciclovir Market Value Share (%), by Patient Age Group, 2021 and 2031
Figure 48: Latin America Valganciclovir Market Attractiveness Analysis, by Patient Age Group, 2022–2031
Figure 49: Latin America Valganciclovir Market Value Share Analysis, by Application, 2021 and 2031
Figure 50: Latin America Valganciclovir Market Attractiveness Analysis, by Application, 2022–2031
Figure 51: Latin America Valganciclovir Market Value Share (%), by Distribution Channel, 2021 and 2031
Figure 52: Latin America Valganciclovir Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 53: Middle East & Africa Valganciclovir Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 54: Middle East & Africa Valganciclovir Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 55: Middle East & Africa Valganciclovir Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 56: Middle East & Africa Valganciclovir Market Value Share (%), by Patient Age Group, 2021 and 2031
Figure 57: Middle East & Africa Valganciclovir Market Attractiveness Analysis, by Patient Age Group, 2022–2031
Figure 58: Middle East & Africa Valganciclovir Market Value Share Analysis, by Application, 2021 and 2031
Figure 59: Middle East & Africa Valganciclovir Market Attractiveness Analysis, by Application, 2022–2031
Figure 60: Middle East & Africa Valganciclovir Market Value Share (%), by Distribution Channel, 2021 and 2031
Figure 61: Middle East & Africa Valganciclovir Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Valganciclovir Market
